Uncategorized Archives - Page 28 of 252

WednesdayFeb 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending Speaking during a late…

TuesdayFeb 07, 2023 10:30 am

REZYFi, Inc. Anticipates Increased Demand for its Services Following Rise in Mortgage Demand

30-year fixed-rate mortgages with conforming loan balances of $726,200 or less, saw rates decrease from 6.42% to 6.23% for the week ending January 18, 2023, resulting in a 28% increase in mortgage application volume, and a 34% increase in refinance demand It is projected that by the end of 2023, mortgage rates in the country will drop by 5.25%, coming from 2022, which saw home financing costs nearly double These rate drops present an opportunity for REZYFi to grow its customer reach, market share, and revenue but also offer an avenue for the growth of the housing finance sector REZYFi,…

TuesdayFeb 07, 2023 9:45 am

SideChannel Inc. (SDCH) Bringing Critical Security to Clients with Tailored Cybersecurity Programs for Mid-Market Companies

Brian recently joined Bell2Bell’s Stuart Smith in a podcast episode in which he discussed his and the company’s background, motivation to found SideChannel, existing market opportunities, 2022 milestones, and plans for 2023 and beyond SideChannel, a provider of cybersecurity services and products, helps mid-market companies simplify cybersecurity The company was founded in 2019 after CEO Brian Haugli observed a business opportunity in the largely underserved market Over the years since, the company has grown, posting $4.8 million in revenue in 2022, up from $2.8 million in 2021 During his stints at the US Department of Defense (“DoD”) and Pentagon, and…

MondayFeb 06, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage to scale up the commercial execution of its technology in 2023 To facilitate this, Lexaria has brought on board Julian Gangolli, former President of GW Pharmaceuticals USA, as a strategic advisor. Chris Bunka, Lexaria’s CEO,…

MondayJan 30, 2023 4:20 am

420 with CNW — US Air Force Grants Cannabis Waivers to More Recruits Than Anticipated

As cannabis reform has swept across the country, there have been questions about how institutions that still abide by prohibitionist cannabis policies would deal with an influx of cannabis users among their ranks. Last September, the U.S. Air Force and Space Force launched a pilot program that would allow recruits who had tested positive for marijuana during the enlistment process to enlist. The two military branches announced last year that while active members were still banned from using cannabis regardless of state laws, new recruits who had high enough scores on their qualification tests, did not have convictions on their…

FridayJan 27, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience recently released its 2023 annual letter from CEO Chris Bunka, providing a strategic update to all stakeholders The letter highlights the key milestones achieved in calendar 2022, outlines expectations for calendar 2023, and indicates why Chris Bunka expects 2023 to be the company’s best year so far 1In calendar 2023, Lexaria expects to attain FDA registration for an investigational new drug (“IND”) program and commence Phase 1(b) clinical study evaluating the safety and tolerability of DehydraTECH(TM)-processed CBD as a treatment for hypertension The company will also be pursuing commercial relationships in 2023 even as its R&D continues to…

WednesdayJan 25, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream…

TuesdayJan 17, 2023 12:00 pm

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://cnw.fm/LGAZG). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter…

FridayJan 13, 2023 10:30 am

REZYFi, Inc. Creates Opportunities for Cannabis Related Real Estate Financing as Mainstream Media Begins to Show Growing Acceptance of Cannabis-Derived Products

Google will change its requirements for product ads on January 20, 2023, to allow the promotion of FDA-approved pharmaceuticals containing CBD and topical hemp-derived CBD products in California, Colorado, and Puerto Rico Non-FDA-approved CBD topicals will require certification from LegitScript, which will test THC compliance and review the third-party Certificate of Analysis of each product to be promoted With the growing acceptance of cannabis, REZYFi is positioned in the financial industry as one of the first cannabis mortgage bankers in the United States In the United States, cannabis-related products are growing in acceptance, even in mainstream media. A recent announcement…

WednesdayJan 11, 2023 11:15 am

REZYFi, Inc. Leverages Cannabis and Real Estate Financing Opportunities Through Wholly-Owned Subsidiaries

The growing perception is that cannabis companies investing in real estate raise the value of the area in which they invest A 2020 study conducted in states where medicinal and recreational cannabis is legal found that 35-36% of respondents saw an increase in demand for warehouses, 23% for storefronts, and up to 28% for land The global legal cannabis market was valued at $17.8 billion in 2021 and is expected to reach $134.4 billion by 2030 REZYFi is leveraging its corporate strengths through two wholly-owned subsidiaries – REZYFi Lending and ResMac Inc. – offering a diversified approach to cannabis and…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

Category: Uncategorized